Literature DB >> 32051538

A predictive CD8+ T cell phenotype for T1DM progression.

F Susan Wong1, Li Wen2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32051538      PMCID： PMC8258660          DOI： 10.1038/s41574-020-0330-3

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Circulating β cell-specific CD8+ T cells restricted by high-risk HLA class I molecules show antigen experience in children with and at risk of type 1 diabetes.

Authors:  L Yeo; I Pujol-Autonell; R Baptista; M Eichmann; D Kronenberg-Versteeg; S Heck; G Dolton; A K Sewell; T Härkönen; M-L Mikk; J Toppari; R Veijola; M Knip; J Ilonen; M Peakman
Journal:  Clin Exp Immunol       Date:  2019-11-10       Impact factor: 4.330
  1 in total
  4 in total

1.  Decreased expression of programmed death-1 on CD8+ effector memory T lymphocytes correlates with the pathogenesis of type 1 diabetes.

Authors:  Yimei Shan; Yinghong Kong; Yan Zhou; Jingjing Guo; Qiyun Shi; Sicheng Li; Heming Guo; Yiting Huang; Sisi Ding; Cuiping Liu; Lei Cao; Yun Huang; Chen Fang; Ji Hu
Journal:  Acta Diabetol       Date:  2021-04-23       Impact factor: 4.280

2.  Efficacy and Safety of Stem Cell Therapy for T1DM: An Updated Systematic Review and Meta-Analysis.

Authors:  Shi-Yi Sun; Yun Gao; Guan-Jian Liu; Yong-Kun Li; Wei Gao; Xing-Wu Ran
Journal:  J Diabetes Res       Date:  2020-10-10       Impact factor: 4.011

Review 3.  T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy.

Authors:  Zhanyan Gao; Yang Feng; Jinhua Xu; Jun Liang
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 4.  Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances.

Authors:  Saumya Nigam; Jack Owen Bishop; Hanaan Hayat; Tahnia Quadri; Hasaan Hayat; Ping Wang
Journal:  Pharmaceutics       Date:  2022-03-15       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.